Mitchell C. Posner to Pancreaticoduodenectomy
This is a "connection" page, showing publications Mitchell C. Posner has written about Pancreaticoduodenectomy.
Connection Strength
1.667
-
Perioperative Gemcitabine?+?Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. Ann Surg Oncol. 2019 Dec; 26(13):4489-4497.
Score: 0.674
-
More harm than good? Ann Surg Oncol. 2014 Sep; 21(9):2817-9.
Score: 0.474
-
Management of the pancreatic stump following pancreaticoduodenectomy. Br J Surg. 1995 Dec; 82(12):1590-7.
Score: 0.130
-
Research gaps in pancreatic cancer research and comparative effectiveness research methodologies. Cancer Treat Res. 2015; 164:165-94.
Score: 0.122
-
Geriatric assessment improves prediction of surgical outcomes in older adults undergoing pancreaticoduodenectomy: a prospective cohort study. Ann Surg. 2014 May; 259(5):960-5.
Score: 0.117
-
Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 trial. Ann Surg Oncol. 2011 Feb; 18(2):337-44.
Score: 0.091
-
A prospective randomized trial of total parenteral nutrition after major pancreatic resection for malignancy. Ann Surg. 1994 Oct; 220(4):436-41; discussion 441-4.
Score: 0.030
-
Distal extrahepatic cholangiocarcinoma presenting as cholangitis. Dig Dis Sci. 2010 Jul; 55(7):1852-5.
Score: 0.022
-
Neoadjuvant therapy for unresectable pancreatic adenocarcinoma. Arch Surg. 1993 May; 128(5):559-64.
Score: 0.007